Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

Haanen et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69dcd18ee3a90a2e2f1332b4 — DOI: https://doi.org/10.1016/j.esmoop.2023.101210

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial· 2016 · 1,210 citations
2. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3· 2008 · 627 citations
3. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma· 2016 · 95 citations
4. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study· 2009 · 2,119 citations
5. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma· 2021 · 1,726 citations